HOME >> BIOLOGY >> NEWS
Addition of topotecan to standard treatment is not recommended for ovarian cancer patients

The drug topotecan does not increase survival for ovarian cancer patients when used with standard chemotherapy in first-line treatment and is not recommended for future use, according to a phase III study in the August 2 issue of the Journal of the National Cancer Institute.

Standard treatment for advanced ovarian cancer involves a combination of carboplatin and paclitaxel. Past studies have shown that this treatment is effective and has low toxicity. However, cancer recurrence and death rates remain high.

Jacobus Pfisterer, M.D., of the Universtitatsklinikum Schleswig-Holstein in Kiel, Germany, and colleagues randomly assigned 1,308 patients with untreated ovarian cancer to receive paclitaxel and carboplatin followed by either topotecan or surveillance. The researchers wanted to know how the drug regimen affected overall survival, progression-free survival, and quality of life.

Topotecan followed by treatment with carboplatin and paclitaxel did not improve patients' length of survival or survival without cancer recurrence. Topotecan treatment increased the frequency of blood-related toxicities and infections, which require extra medical care. The authors suggest that topotecan should not be used as part of first-line treatment in ovarian cancer patients.

The authors write, "Carboplatin-paclitaxel remains the standard of care for patients with advanced ovarian cancer."

In an accompanying editorial, William P. McGuire, M.D., of the Weinberg Cancer Institute in Baltimore, Md., discusses problems with chemotherapy trials for ovarian cancer, and suggests targeted therapies, such as angiogenesis inhibitors should be considered for future trials. He writes, "It seems that we are at a turning point in the design of clinical trials for ovarian cancer. We can continue to ask easier and, in my opinion, less important questions [...] Or we can 'bite the bullet' and use all of our valuable patient resources to
'"/>

Contact: Ariel Whitworth
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
1-Aug-2006


Page: 1 2

Related biology news :

1. Additional mammogram readers improve breast cancer detection
2. UC experts detail new standard for cleaner transportation fuels
3. DOE JGI sets gold standard for metagenomic data analysis
4. Enhancing chemotherapys efficacy: New agent has synergistic effect with standard drugs
5. UN, industry, others partner to create world standards for e-scrap recycling, harvesting components
6. AAAS applauds nationwide science and math standards based on existing guidelines
7. Study of toxins in Houston air warrants new standards
8. Neurologists developing first standardized measurement scale for dyskinesia in Parkinsons patients
9. Nilotinib appears to help chronic myelogenous leukemia patients when standard care fails
10. RNAi Global Initiative members advance standards for genome-wide RNAi research in second meeting
11. Newborn hearing screening programs may benefit from the standardization of testing protocols

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... August 19, 2020 , ... ... expo uniting life science, data science, informatics and IT leaders goes VIRTUAL and ... period of uncertainty and change, Bio-IT takes the leadership role of keeping our ...
(Date:8/7/2020)... LOUISVILLE, Ky. (PRWEB) , ... August 06, 2020 ... ... been selected to participate in the prestigious National STEM Scholar Program, a unique ... national network building, and project support for middle school science teachers nationwide. , ...
(Date:7/22/2020)... ... July 21, 2020 , ... USDM Life ... and compliance, announces a new solution to manage regulated workloads on Microsoft Azure. ... their technology stack complies with FDA and global regulations. USDM's new managed service ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... today announced the launch of its new tagline, “BUILDING FOR LIFE.” The adoption ... industry and around the globe, requiring fast track capacity to provide patients with ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... the top radiation centers in 16 countries, has reached its 20th anniversary of ... now in routine use at top universities including University of Pennsylvania, University of ...
(Date:7/18/2020)... ... July 16, 2020 , ... ... the early detection and prevention of high-burden diseases, and Centric Consulting, a business ... healthcare organizations to utilize existing data in order to identify and prioritize patients ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage ... Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson ... product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at ...
Breaking Biology Technology:
Cached News: